Skip to main content
Premium Trial:

Request an Annual Quote

Lentigen, Dharmacon, Qiagen, Sigma-Aldrich

Premium
Lentigen and Dharmacon have recently introduced Smartvector shRNA lentiviral particles, which combine Dharmacon’s gene-silencing reagents with Lentigen’s LentiMax lentiviral vector technology.
 
According to the companies, the particles are capable of expressing highly functional shRNA that efficiently and stably silences gene expression in a wide variety of cells.  
 

 
Qiagen recently announced that its HP validated siRNAs will be provided with full sequence information at no additional cost.
 
According to the company, the full sequence information provides data for analysis of experimental results and verification of knockdown.
 

 
Sigma-Aldrich has launched the LentiExpress shRNA-based system, which is designed to allow rapid high-throughput RNAi screening with minimal reagent preparation or optimization.
 
According to the company, the system consists of pre-arrayed lentiviral particles harboring shRNAs from the RNAi Consortium collection.
The system is currently available with the RNAi Consortium’s human kinase shRNA collection, and includes 3,109 individual pre-arrayed lentiviral clones harboring shRNA sequences that target 673 human kinase genes for gene silencing.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.